GLP1R and cancer: Another meta-analysis published in 2017 that included four large-scale studies indicated that GLP-1 receptor agonists did not increase the risk of pancreatic cancer [51], and our study further demonstrated that GLP-1 receptor agonist therapy was not associated with an increased risk of any of the malignant neoplasms studied.